For the study, published Aug. 15 in Journal of Infectious Diseases, researchers compared the outcomes of 2,833 high-risk COVID-19 patients treated with bebtelovimab and 774 patients treated with Pfizer’s antiviral Paxlovid.
Just 1.4 percent of patients taking bebtelovimab developed serious illness within 30 days, a comparable rate to Paxlovid and other monoclonal antibody treatments used before BA.2 gained dominance in the U.S. earlier this year. This finding is significant, as bebtelovimab was cleared for emergency use in February based on limited data as an alternative therapy for high-risk patients who couldn’t take remdesivir or Paxlovid.
“This study gives us confidence that bebtelovimab is reliable for the treatment of high-risk patients during this omicron epoch characterized by increasingly new variants, and gives us another tool in the effort against COVID-19,” lead study author Raymund Razonable, MD, an infectious diseases specialist and researcher at Mayo Clinic, said in a news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
